title: Beta amyloid imaging with positron emission tomography (PET) for evaluation of suspected Alzheimer's disease or other causes of cognitive decline.
mesh_terms: D000544:Alzheimer Disease / Q000000981:diagnostic imaging / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000032:analysis*; D000814:Aniline Compounds; D054598:Blue Cross Blue Shield Insurance Plans; D001921:Brain / Q000000981:diagnostic imaging* / Q000473:pathology; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000000981:diagnostic imaging* / Q000473:pathology; D018795:Device Approval; D005026:Ethylene Glycols; D006801:Humans; D058225:Plaque, Amyloid / Q000150:complications / Q000000981:diagnostic imaging* / Q000473:pathology; D049268:Positron-Emission Tomography / Q000379:methods*; D013673:Technology Assessment, Biomedical; D016896:Treatment Outcome; D014481:United States
chemical_list: D016229:Amyloid beta-Peptides; D000814:Aniline Compounds; D005026:Ethylene Glycols